Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study | Health & Environmental Research Online (HERO)

Health & Environmental Research Online (HERO)

Print Feedback Export to File

This record has one attached file:

Citation
Tags

HERO ID

7046420

Reference Type

Journal Article

Title

Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study

Author(s)

Bourne, RRA; Kaarniranta, K; Lorenz, K; Traverso, CE; Vuorinen, J; Ropo, A; ,

Year

2019

Is Peer Reviewed?

Journal

BMJ Open
EISSN: 2044-6055

Publisher

BMJ PUBLISHING GROUP

Location

LONDON

Language

English

PMID

30944129

DOI

10.1136/bmjopen-2018-024129

Web of Science Id

WOS:000471157200042

Abstract

Bimatoprost-timolol (bimatoprost 0.03%-timolol 0.5% fixed-dose combination [FDC]) and tafluprost-timolol (tafluprost 0.0015%-timolol 0.5% FDC) eye drops are currently the only topical intraocular pressure (IOP)-reducing therapies available as preservative-free (PF) prostaglandin and timolol FDC. The aim of this study was to investigate changes to ocular signs and symptoms when patients with ocular hypertension (OH) or open-angle glaucoma (OAG) switched from PF or benzalkonium chloride (BAK)-preserved bimatoprost-timolol to PF tafluprost-timolol eye drops.